ANTIATHEROGENIC EFFECTS OF CALCIUM-CHANNEL BLOCKERS - POSSIBLE MECHANISMS OF ACTION

被引：15

作者：

HENRY, PD

机构：

[1] Molecular Physiology and Biophysics, Baylor College of Medicine, Houston, 77030, TX, One Baylor Plaza

来源：

CARDIOVASCULAR DRUGS AND THERAPY | 1990年 / 4卷

关键词：

ATHEROSCLEROSIS; NIFEDIPINE; VERAPAMIL; DILTIAZEM;

D O I：

10.1007/BF02018310

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Calcium-channel blockers (Ca blockers), such as nifedipine, verapamil, diltiazem, flunarizine, and their respective derivatives, have been reported to suppress the formation of arterial lesions in animals fed atherogenic diets. The fact that structurally unrelated Ca blockers exert similar antiatherogenic effects may suggest that the drugs act by a calcium-channel-dependent mechanism. However, in cell culture experiments in which putative antiatherosclerotic effects were observed only in the presence of a very high drug concentration ( > 10 mu-M), calcium-channel-independent mechanisms are likely. It does not appear that Ca blockers act predominantly by altering coronary risk factors such as arterial pressure or hypercholesterolemia. On the other hand, current evidence is accumulating that Ca blockers may act by suppressing chemotaxis and the proliferation of cells involved in lesion formation. Recent reports indicate that relatively low concentrations ( < 1 mu-M) of nifedipine may promote the release of cholesterol from fat-laden smooth cells and macrophages. Controlled clinical trials are needed to determine whether Ca blockers have utility in the prevention of the progression of atherosclerosis in humans.

引用

页码：1015 / 1020

页数：6

共 52 条

[1]

Betz E., The effect of calcium antagonists on intimal cell proliferation in atherogenesis, Ann NY Acad Sci, 522, pp. 399-410, (1988)

[2]

Betz E., Hammerle H., Strohschneider T., Inhibition of smooth muscle cell proliferation and endothelial permeability with flunarizine in vitro and in experimental atheromas, Res Exp Med, 185, pp. 325-340, (1985)

[3]

Blumlein S.L., Sievers R., Kidd P., Parmley W.W., Mechanism of protection from atherosclerosis by verapamil in the cholesterol-fed rabbit, Am J Cardiol, 54, pp. 884-889, (1984)

[4]

Bossaller C., Habib G.B., Yamamoto H., Et al., Impaired muscarinic endothelium-dependent relaxation and cyclic guanosine 5′-monophosphate formation in atherosclerotic human coronary artery and rabbit aorta, J Clin Invest, 79, pp. 170-174, (1987)

[5]

Bretherton K.N., Day A.J., Skinner S.L., Hypertension-accelerated atherogenesis in cholesterol-fed rabbits, Atherosclerosis, 27, pp. 79-87, (1977)

[6]

Catapano A.L., Maggi F.M., Cicerano U., The antiatherosclerotic effect of anipamil in cholesterol-fed rabbits, Ann NY Acad Sci, 522, pp. 519-521, (1988)

[7]

Corsini A., Fumagalli R., Paoletti R., Calcium antagonists and low density lipoproteins metabolism by human fibroblasts and by human hepatoma cell line HEP G2, Pharmac Res Comm, 18, pp. 1-16, (1986)

[8]

Daugherty A., Rateri D.L., Sehonfeld G., Sobel B.E., Inhibition of choleteryl ester deposition in macrophages by calcium entry blockers: An effect dissociable from calcium entry blockade, Br J Pharmacol, 91, pp. 113-118, (1987)

[9]

Diccianni M.B., Cardin A.D., Britt A.L., Et al., Effect of a sustained release formulation of diltiazem on the development of atherosclerosis in cholesterol-fed rabbits, Atherosclerosis, 65, pp. 199-205, (1987)

[10]

Etingin O.R., Hajjar D.P., Nifedipine increases cholesteryl ester hydrolytic activity in lipid-laden rabbit arterial smooth muscle cells, J Clin Invest, 75, pp. 1554-1558, (1985)

← 1 2 3 4 5 6 →